“…The preclinical results showed that anlotinib can significantly inactivate FGFR1–4, especially FGFR2 [ 39 ]. Lung adenocarcinoma patients with FGFR2 fusion may benefit from anlotinib [ 40 ]. In this study, we confirmed that FGF6 amplification can not only promote the phosphorylation of FGFR, but also promote the phosphorylation of AKT/ERK pathway.…”